TY - JOUR
T1 - Deep-learning-based target screening and similarity search for the predicted inhibitors of the pathways in Parkinson's disease
AU - Khan, Abbas
AU - Chandra Kaushik, Aman
AU - Ali, Syed Shujait
AU - Ahmad, Nisar
AU - Wei, Dong Qing
N1 - Funding Information:
This work is supported by the grants from the Key Research Area Grant 2016YFA0501703 of the Ministry of Science and Technology of China, the National Natural Science Foundation of China (Contract No. 61832019, 61503244), the Natural Science Foundation of Henan Province (162300410060) and Joint Research Funds for Medical and Engineering and Scientic Research at Shanghai Jiao Tong University (YG2017ZD14). The computations were partially performed at the Center for High-Performance Computing, Shanghai Jiao Tong University.
Publisher Copyright:
© 2019 The Royal Society of Chemistry.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Herein, a two-step de novo approach was developed for the prediction of piperine targets and another prediction of similar (piperine) compounds from a small molecule library using a deep-learning method. Deep-learning and neural-network approaches were used for target prediction, similarity searches, and validation. The present approach was trained on records containing the data. The model attained an overall accuracy of around 87.5%, where the training and test set was kept as 70% and 30% (17226/40197), respectively. This method predicted two targets (MAO-A and MAO-B) and 101 compounds as piperine derivatives. MAO-A and MAO-B are important drug targets in Parkinson's disease. Validation of this method was also performed by considering piperine and its targets (monoamine oxidase A and B) using molecular docking, dynamics simulation and post-simulation analysis of all the selected compounds. Rasagiline, lazabemide, and selegiline were selected as controls, which are already FDA-approved drugs against these targets. Molecular docking studies of the FDA-approved drugs and the compounds we predicted using DL and neural networks were carried out against MAO-A and MAO-B. Using the molecular docking's scoring function, molecular dynamics simulation and free energy calculations as extended validation methods, it was observed that the compounds predicted herein possessed excellent inhibitory effects against the selected targets. Thus, deep learning may play a very effective role in predicting the potential compounds, their targets and can play an expanded role in computer-aided drug approaches.
AB - Herein, a two-step de novo approach was developed for the prediction of piperine targets and another prediction of similar (piperine) compounds from a small molecule library using a deep-learning method. Deep-learning and neural-network approaches were used for target prediction, similarity searches, and validation. The present approach was trained on records containing the data. The model attained an overall accuracy of around 87.5%, where the training and test set was kept as 70% and 30% (17226/40197), respectively. This method predicted two targets (MAO-A and MAO-B) and 101 compounds as piperine derivatives. MAO-A and MAO-B are important drug targets in Parkinson's disease. Validation of this method was also performed by considering piperine and its targets (monoamine oxidase A and B) using molecular docking, dynamics simulation and post-simulation analysis of all the selected compounds. Rasagiline, lazabemide, and selegiline were selected as controls, which are already FDA-approved drugs against these targets. Molecular docking studies of the FDA-approved drugs and the compounds we predicted using DL and neural networks were carried out against MAO-A and MAO-B. Using the molecular docking's scoring function, molecular dynamics simulation and free energy calculations as extended validation methods, it was observed that the compounds predicted herein possessed excellent inhibitory effects against the selected targets. Thus, deep learning may play a very effective role in predicting the potential compounds, their targets and can play an expanded role in computer-aided drug approaches.
UR - http://www.scopus.com/inward/record.url?scp=85063931453&partnerID=8YFLogxK
U2 - 10.1039/c9ra01007f
DO - 10.1039/c9ra01007f
M3 - Article
AN - SCOPUS:85063931453
VL - 9
SP - 10326
EP - 10339
JO - RSC Advances
JF - RSC Advances
SN - 2046-2069
IS - 18
ER -